ADRB2 and asthma: If cysteinyl-LTs released from resident or circulating inflammatory cells or even from the smooth muscle cell itself are the major responsible for β2-AR desensitization in asthma, then the concurrent administration of CysLT1R antagonists may represent a useful tool to improve the response to β2-AR agonists in this disease.